Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00487123 |
This study will evaluate the efficacy of the reminder device Remind Cap® in improving patients' compliance in the consumption of Valsartan +/- Hydrochlorothiazide (HCTZ) in the treatment of hypertension
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Valsartan+/- Hydrochlorothiazide |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multi-Center, Randomized, Proof-of-Concept, Parallel Control Study With Remind Cap® in Patients With Essential Hypertension and Newly Treated With Valsartan+/-Hydrochlorothiazide (HCTZ) |
Study Completion Date: | September 2007 |
Primary Completion Date: | September 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Study ID Numbers: | CVAH631BSG02 |
Study First Received: | June 13, 2007 |
Last Updated: | June 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00487123 History of Changes |
Health Authority: | United States: Food and Drug Administration; Singapore: Health Sciences Authority |
Hypertension, compliance, Valsartan, hydrochlorothiazide (HCTZ) |
Essential Hypertension Sodium Chloride Symporter Inhibitors Diuretics Vascular Diseases Cardiovascular Agents |
Antihypertensive Agents Hydrochlorothiazide Valsartan Hypertension |
Molecular Mechanisms of Pharmacological Action Diuretics Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Vascular Diseases Cardiovascular Agents Antihypertensive Agents Hydrochlorothiazide |
Pharmacologic Actions Membrane Transport Modulators Natriuretic Agents Therapeutic Uses Cardiovascular Diseases Valsartan Hypertension |